MedTrace Logo

Dose-Response Curve: Interventions to Prevent and Treat Radiodermatitis

NCT02249884 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-12-02

No results posted yet for this study

Summary

Dose response curve to define the security and tolerable dose to be used for prevention and treatment of radiodermatitis in patients with breast or head and neck cancer.

Conditions

  • Radiodermatitis

Interventions

DRUG

Urea Dose A

Urea cream for topical use.

DRUG

Urea Dose B

Urea cream for topical use.

DRUG

Urea Dose C

Urea cream for topical use.

DRUG

Chamomile Dose A

Chamomile gel for topical use.

DRUG

Chamomile Dose B

Chamomile gel for topical use.

DRUG

Chamomile Dose C

Chamomile gel for topical use.

Sponsors & Collaborators

Principal Investigators

  • Paula Elaine D Reis, RN PhD · University of Brasilia

  • Marcia A Ciol, PhD · University of Washington

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2015-03-31
Completion
2015-11-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02249884 on ClinicalTrials.gov